FULC - CIK 0001680581
Fulcrum Therapeutics, Inc. (FULC) reported net income of -$74.88M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$74.88M | -669.6% |
| FY 2024 | -$9.73M | +90.0% |
| FY 2023 | -$97.34M | +11.4% |
| FY 2022 | -$109.87M | -35.9% |
| FY 2021 | -$80.85M | -14.2% |
| FY 2020 | -$70.82M | +14.3% |
| FY 2019 | -$82.68M | -153.7% |
| FY 2018 | -$32.59M | - |
Fulcrum Therapeutics, Inc. (FULC) reported net income of -$74.88M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Fulcrum Therapeutics, Inc.'s net income declined from -$32.59M to -$74.88M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.